Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study

Egeli B. H., Ergun S., Cetin A., Gursoy Y. K., UĞURLU S.

CLINICAL RHEUMATOLOGY, vol.41, no.1, pp.123-127, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.1007/s10067-021-05871-9
  • Journal Name: CLINICAL RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.123-127
  • Keywords: Dermatomyositis, Polymyositis, Rituximab, POLYMYOSITIS, THERAPY, DERMATOMYOSITIS, EFFICACY
  • Istanbul University Affiliated: No

Abstract

Background Idiopathic inflammatory myopathies (IIM) are essentially treated aiming to improve muscle function and extra muscular disease manifestations. Rituximab is potentially a glucocorticoid-sparing agent which was reviewed in multiple studies with small sample sizes due to the rarity of the disease. Higher statistical power can enhance the trustworthiness of alternative treatment modalities yielding the main objective of this study.